The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C
Abstract
To elucidate the risk factors for liver carcinogenesis and to examine the incidence of hepatocellular carcinoma (HCC) after interferon therapy, 1,022 chronic hepatitis C patients treated with interferon were followed by ultrasonography for 13 to 97 months (median 36 months). Sustained response with prolonged alanine aminotransferase normalization was found in 313 patients, transient response with alanine aminotransferase relapse after therapy in 304, and no response in 405. Forty-six developed HCC, of whom 5 were sustained responders, 9 were transient responders, and 32 were nonresponders. The cumulative incidence of HCC in transient responders was almost equal to that in sustained responders, and it was significantly higher in nonresponders than in sustained and transient responders (P = .0009). The seventh-year cumulative incidence rates of HCC in sustained responders, transient responders, and nonresponders were estimated to be 4.3%, 4.7%, and 26.1%, respectively. However, there was no significant difference in the cumulative incidence of HCC between patients with HCV subtype 1 and 2 (P = .14). Cox regression analysis showed that the risk of HCC development was not elevated in transient responders compared with sustained responders, but that the risk was 7.90-fold higher in nonresponders than in sustained responders (P = .008). Patients ≥55 years of age had a significantly higher risk ratio (4.65) than did those under 55 years of age (P = .006). The risk of HCC development in men was 4.35 times higher than the risk in women (P = .02). However, the degree of fibrosis was not a significant risk factor for the development of HCC (risk ratio, 3.16; P = .052). These results suggest that patients in the high-risk group of HCC after interferon therapy were those who showed no response, those who were older, and those who were male, and that such patients should be carefully followed using ultrasonography.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Knodell, R. G., Ishak, K. G., Black, W. C., Chen, T. S., Craig, R., Kaplowitz, N., Kiernan, T. W., & Wollman, J. (1981) · Hepatology · doi:10.1002/hep.1840010511 · Cited by 3,522
Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa
Davis, G. L., Balart, L. A., Schiff, E. R., Lindsay, K., Bodenheimer, H. C., Perrillo, R. P., Carey, W., Jacobson, I. M., Payne, J., Dienstag, J. L., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911303212203 · Cited by 1,633
Fattovich, G., Giustina, G., Degos, F., Tremolada, F., Diodati, G., Almasio, P., Nevens, F., Solinas, A., Mura, D., Brouwer, J., et al. (1997) · Gastroenterology · doi:10.1053/gast.1997.v112.pm9024300 · Cited by 1,399
Okamoto, H., Sugiyama, Y., Okada, S., Kurai, K., Akahane, Y., Sugai, Y., Tanaka, T., Sato, K., Tsuda, F., Miyakawa, Y., et al. (1992) · Journal of General Virology · doi:10.1099/0022-1317-73-3-673 · Cited by 1,242
Kiyosawa, K., Sodeyama, T., Tanaka, E., Gibo, Y., Yoshizawa, K., Nakano, Y., Furuta, S., Akahane, Y., Nishioka, K., Purcell, R. H., et al. (1990) · Hepatology · doi:10.1002/hep.1840120409 · Cited by 1,217
Self-citationRecombinant Interferon Alfa Therapy for Chronic Hepatitis C
Di Bisceglie, A. M., Martin, P., Kassianides, C., Lisker-Melman, M., Murray, L., Waggoner, J., Goodman, Z., Banks, S. M., & Hoofnagle, J. H. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911303212204 · Cited by 1,212
Risk Factors for Hepatocellular Carcinoma among Patients with Chronic Liver Disease
Tsukuma, H., Hiyama, T., Tanaka, S., Nakao, M., Yabuuchi, T., Kitamura, T., Nakanishi, K., Fujimoto, I., Inoue, A., Yamazaki, H., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306243282501 · Cited by 1,126
A proposed system for the nomenclature of hepatitis C viral genotypes
Simmonds, P., Alberti, A., Alter, H. J., Bonino, F., Bradley, D. W., Brechot, C., Brouwer, J. T., Chan, S.-W., Chayama, K., Chen, D.-S., et al. (1994) · Hepatology · doi:10.1002/hep.1840190538 · Cited by 1,023
Nishiguchi, S., Kuroki, T., Nakatani, S., Morimoto, H., Takeda, T., Nakajima, S., Shiomi, S., Seki, S., Kobayashi, K., & Otani, S. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91739-x · Cited by 857
Significance of serum hepatitis C virus RNA levels in chronic hepatitis C
Lau, J. Y. N., Davis, G. L., Kniffen, J., Qian, K.-P., Urdea, M. S., Chan, C. S., Neuwald, P. D., Wilber, J. C., & Mizokami, M. (1993) · The Lancet · doi:10.1016/0140-6736(93)90635-t · Cited by 795
Cited by
Omata, M., Cheng, A.-L., Kokudo, N., Kudo, M., Lee, J. M., Jia, J., Tateishi, R., Han, K.-H., Chawla, Y. K., Shiina, S., et al. (2017) · Hepatology International · doi:10.1007/s12072-017-9799-9 · Cited by 2,171
Imamura, H., Matsuyama, Y., Tanaka, E., Ohkubo, T., Hasegawa, K., Miyagawa, S., Sugawara, Y., Minagawa, M., Takayama, T., Kawasaki, S., et al. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00360-4 · Cited by 1,589
Yoshida, H., Shiratori, Y., Moriyama, M., Arakawa, Y., Ide, T., Sata, M., Inoue, O., Yano, M., Tanaka, M., Fujiyama, S., et al. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-3-199908030-00003 · Cited by 1,096
The Natural History of Hepatitis C Virus Infection: Host, Viral, and Environmental Factors
Thomas, D. L., Astemborski, J., Rai, R. M., Anania, F. A., Schaeffer, M., Galai, N., Nolt, K., Nelson, K. E., Strathdee, S. A., Johnson, L., et al. (2000) · JAMA · doi:10.1001/jama.284.4.450 · Cited by 1,073
Kudo, M., Izumi, N., Kokudo, N., Matsui, O., Sakamoto, M., Nakashima, O., Kojiro, M., Makuuchi, M., & for the HCC Expert Panel of Japan Society of Hepatology (2011) · Digestive Diseases · doi:10.1159/000327577 · Cited by 825
Bruno, S., Stroffolini, T., Colombo, M., Bollani, S., Benvegnù, L., Mazzella, G., Ascione, A., Santantonio, T., Piccinino, F., Andreone, P., et al. (2007) · Hepatology · doi:10.1002/hep.21492 · Cited by 604
Hepatitis C and hepatocellular carcinoma
Di Bisceglie, A. M. (1997) · Hepatology · doi:10.1002/hep.510260706 · Cited by 558
Outcome of Sustained Virological Responders With Histologically Advanced Chronic Hepatitis C†,‡,§,¶
Morgan, T. R., Ghany, M. G., Kim, H.-Y., Snow, K. K., Shiffman, M. L., De Santo, J. L., Lee, W. M., Di Bisceglie, A. M., Bonkovsky, H. L., Dienstag, J. L., et al. (2010) · Hepatology · doi:10.1002/hep.23744 · Cited by 479
Benvegnù, L., Gios, M., Boccato, S., & Alberti, A. (2004) · Gut · doi:10.1136/gut.2003.020263 · Cited by 454
Schafer, D. F., & Sorrell, M. F. (1999) · The Lancet · doi:10.1016/s0140-6736(98)09148-x · Cited by 453
Lin, S.-M., Sheen, I.-S., Chien, R.-N., Chu, C.-M., & Liaw, Y.-F. (1999) · Hepatology · doi:10.1002/hep.510290312 · Cited by 444
Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults
Ryder, S. D. (2003) · Gut · doi:10.1136/gut.52.suppl_3.iii1 · Cited by 422
Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death
Degos, F., Christidis, C., Ganne-Carrie, N., Farmachidi, J.-P., Degott, C., Guettier, C., Trinchet, J.-C., Beaugrand, M., & Chevret, S. (2000) · Gut · doi:10.1136/gut.47.1.131 · Cited by 370
Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach
Cammà, C., Giunta, M., Andreone, P., & Craxı̀, A. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00005-8 · Cited by 356
Ikeda, K., Arase, Y., Saitoh, S., Kobayashi, M., Suzuki, Y., Suzuki, F., Tsubota, A., Chayama, K., Murashima, N., & Kumada, H. (2000) · Hepatology · doi:10.1053/jhep.2000.9409 · Cited by 354
Hepatocellular carcinoma: Recent trends in Japan
Kiyosawa, K., Umemura, T., Ichijo, T., Matsumoto, A., Yoshizawa, K., Gad, A., & Tanaka, E. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.012 · Cited by 308
Self-citationShiratori, Y., Shiina, S., Teratani, T., Imamura, M., Obi, S., Sato, S., Koike, Y., Yoshida, H., & Omata, M. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-4-200302180-00008 · Cited by 274
Prevention of Second Primary Tumors by an Acyclic Retinoid in Patients with Hepatocellular Carcinoma
Muto, Y., Moriwaki, H., & Saito, A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904013401315 · Cited by 265
Natural history of hepatitis C: Its impact on clinical management
Di Bisceglie, A. M. (2000) · Hepatology · doi:10.1053/he.2000.5762 · Cited by 263
Impact of oestrogens on the progression of liver disease
Shimizu, I. (2003) · Liver International · doi:10.1034/j.1600-0676.2003.00811.x · Cited by 207
Reduction of hepatocarcinogenesis by ursodeoxycholic acid in rats
Oyama, K. (2002) · Carcinogenesis · doi:10.1093/carcin/23.5.885 · Cited by 50
Metadata
- Authors
- Kasahara, A., Hayashi, N., Mochizuki, K., Takayanagi, M., Yoshioka, K., Kakumu, S., Iijima, A., Urushihara, A., Kiyosawa, K., Okuda, M., Hino, K., & Okita, K.
- Venue
- Hepatology
- Published
- 1998-05
- Volume
- 27
- Issue
- 5
- Pages
- 1394-1402
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2012002512
- Cited by
- 467
- References
- 33
- FWCI
- 28.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.